Sutro Biopharma
STRO • NASDAQ
Sutro Biopharma is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Jane Chung, with a market cap of $404.7M.
CEOJane Chung
Next Earnings
Upcoming earnings announcement for Sutro Biopharma
Date
Thursday, May 7, 2026 (in a month)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$3.41
Revenue Estimate
$8.2M
Earnings History
Past 12 earnings reports for Sutro Biopharma
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 23, 2026 | Q4 2025 | -$5.29Est: -$4.52 | -17.0% | $11.6MEst: $8.6M | +34.9% |  10-K |
| Nov 6, 2025 | Q3 2025 | -$0.67Est: -$0.37 | -81.1% | $9.7MEst: $8.8M | +10.1% | 10-Q |
| Aug 7, 2025 | Q2 2025 | -$0.14Est: -$0.47 | +70.2% | $63.7MEst: $15.0M | +324.1% | 10-Q |
| May 8, 2025 | Q1 2025 | -$0.91Est: -$0.92 | +1.1% | $17.4MEst: $9.0M | +93.3% | 10-Q |
| Mar 13, 2025 | Q4 2024 | -$0.89Est: -$0.95 | +6.3% | $14.8MEst: $12.2M | +21.6% | 10-K |
| Nov 13, 2024 | Q3 2024 | -$0.59Est: -$0.73 | +19.2% | $8.5MEst: $15.3M | -44.1% | 10-Q |
| Aug 13, 2024 | Q2 2024 | -$0.59Est: -$0.79 | +25.3% | $25.7MEst: $21.0M | +22.3% | 10-Q |
| May 13, 2024 | Q1 2024 | -$0.95Est: -$0.86 | -10.5% | $13.0MEst: $12.0M | +8.7% | 10-Q |
| Mar 25, 2024 | Q4 2023 | $0.52Est: -$0.82 | +163.4% | $113.7MEst: $11.8M | +862.9% | 10-K |
| Nov 13, 2023 | Q3 2023 | -$0.81Est: -$0.74 | -9.5% | $16.9MEst: $12.6M | +34.2% | — |
| Aug 10, 2023 | Q2 2023 | -$0.64Est: -$0.73 | +12.3% | $10.4MEst: $12.6M | -17.1% | 10-Q |
| May 15, 2023 | Q1 2023 | -$0.85Est: -$0.81 | -4.9% | $12.7MEst: $11.1M | +13.8% | — |